Jefferies Maintains a 'Buy' on Neurocrine (NBIX); Incrementally Encouraged on VMAT Program

Jefferies maintains a 'Buy' on Neurocrine (NASDAQ: NBIX) price target of $13.00.

Analyst, Thomas Wei, said, "After recent mixed data from the Phase 2 study, we are incrementally encouraged by evidence of inconsistent AIMS scoring in two of five 50 mg dose patients at the center excluded from post-hoc analysis and by new measures in upcoming studies to ensure more robust scoring. Questions remain on the data, but we continue to believe the signal of efficacy warrants further development. 854 represents upside to our valuation."

For an analyst ratings summary and ratings history on Neurocrine click here. For more ratings news on Neurocrine click here.

Shares of Neurocrine closed at $7.95 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Cummins (CMI) PT Lowered to $675 at Jefferies
• Ferrovial SA (FER:SM) (FRRVF) Reiterated at Buy by UBS on Winning Bid For Tennessee Project
• Benchmark Reiterates Buy Rating on Rank One Computing (ROC)